Location of Repository

Assessment of Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs using Brain Microdialysis

By Pooja Sood

Abstract

In order to assess pharmacokinetics and pharmacodynamics (PK/PD) accurately, it is necessary to obtain measurements of the absolute concentrations of compounds in the brain. A major shortcoming of using microdialysis to measure PK/PD is that microdialysis measurements do not give us absolute concentrations of solutes in the brain, since the relationship between dialysate concentrations and true extracellular fluid (ecf) concentrations surrounding the probe is unknown. Several methods have been devised to circumvent this problem. The present study employed a novel method, MetaQuant (MQ) microdialysis, which achieves near 100% recovery, and so enables the measurement of absolute ecf concentrations. I examined the effect of the D4 receptor agonist, PD168077 on extracellular dopamine levels (that is PD) in medial prefrontal cortex (mPFC) and nucleus accumbens (NAc) of freely moving rats, while simultaneously measuring brain concentrations (that is PK) of the drug. Thus we were able to estimate the PK/PD profile of the drug in the two brain regions. Compared with basal extracellular levels, subcutaneous administration of PD168077 caused significant increase in dopamine in mPFC. Activation of dopamine D4 receptors in the mPFC may improve cognitive function, which is highly impaired in individuals with schizophrenia. Moreover, it has been consistently shown that phencyclidine (PCP) produces robust cognitive disruption, in a novel object recognition (NOR) test. I studied the efficacy of PD168077 to attenuate sub-chronic PCP induced deficit in the NOR task. Sub-chronic PCP induced a robust cognitive disruption and PD168077 (10 mg/kg, s.c. dose) reversed this disruption. Further MQ dialysis data showed that PD168077 (10 mg/kg, s.c. dose) increased dopamine levels in mPFC that was depleted due to PCP suggesting a mechanism for the observed alleviation of PCP induced cognitive deficits

Publisher: University of Leicester
Year: 2010
OAI identifier: oai:lra.le.ac.uk:2381/8820

Suggested articles

Preview

Citations

  1. (2006). [35S]GTPgammaS binding at the human dopamine D4 receptor variants hD4.2, hD4.4 and hD4.7 following stimulation by dopamine, epinephrine and norepinephrine.
  2. (2004). [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
  3. (1999). [Atypical antipsychotic profiles of sigma receptor ligands].
  4. (1991). 66Ga--a promising isotope for positron emission tomography.
  5. (1991). A comparison between three methods for estimation of extracellular concentration of exogenous and endogenous compounds by microdialysis .
  6. (2004). A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.
  7. (1999). A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia.
  8. (1987). A microdialysis method allowing characterization of intercellular water space in humans.
  9. (1988). A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data.
  10. (1964). A Rapid and Simple Radioassay for Tyrosine Hydroxylase Activity.
  11. (2005). A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats.
  12. (2007). AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives.
  13. (2001). Accumbens dopamine mechanisms in sucrose intake.
  14. (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.
  15. (1990). Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study.
  16. (2004). Altered brain exposure of morphine in experimental meningitis studied with microdialysis.
  17. (1990). Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine.
  18. (2005). Amphetamine induces dopamine efflux through a dopamine transporter channel.
  19. (1995). Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport.
  20. (1993). Amphetamine: effects on catecholamine systems and behavior.
  21. (1999). An integrated view of pathophysiological models of schizophrenia.
  22. (1994). An investigation of the origin of extracellular GABA in rat nucleus accumbens measured in vivo by microdialysis.
  23. (1995). Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat.
  24. (1992). Analysis of zidovudine distribution to specific regions in rabbit brain using microdialysis.
  25. (2008). and Young A
  26. (1993). Animal models of human genetic diseases.
  27. (2004). Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia.
  28. (1990). Animal models with construct validity for schizophrenia.
  29. (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis.
  30. (2007). Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine.
  31. (1975). Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons.
  32. (2001). Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects.
  33. (1999). Antipsychotics from theory to practice: integrating clinical and basic data.
  34. (2009). Appendix List of publications and conference
  35. (2003). Assaying protein unbound drugs using microdialysis techniques.
  36. (2007). Atypical antipsychotics attenuate a subchronic PCP-induced cognitive deficit in the novel object recognition task in the rat.
  37. (2001). Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
  38. (1995). Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment.
  39. (2003). Basal and morphine-evoked dopaminergic neurotransmission in the nucleus accumbens of MOR- and DOR-knockout mice.
  40. (1982). Behavioral effects of chronic phencyclidine administration in rats.
  41. (1989). Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes.
  42. (2009). Behavioural and neurochemical effects of D4 receptor agonist; PD 168077: measurement of absolute brain concentrations of dopamine using microdialysis.
  43. (1997). Behavioural pharmacology of the non-competitive NMDA antagonists dextrorphan and ADCI: relations between locomotor stimulation, anticataleptic potential and forebrain dopamine metabolism.
  44. (2004). Bidirectional regulation of Ca2+/calmodulin-dependent protein kinase II activity by dopamine D4 receptors in prefrontal cortex.
  45. (1997). Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.
  46. (1998). Blood-brain barrier equilibration of codeine in rats studied with microdialysis.
  47. (2001). Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.
  48. (2001). Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors.
  49. (1995). Brain microdialysis and its application for the study of animal behaviour.
  50. (1989). Brain microdialysis.
  51. (1975). Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
  52. (1998). Carriermediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter.
  53. (2000). Catching up on schizophrenia: natural history and neurobiology.
  54. (1997). Cellular distribution of the rat D4 dopamine receptor protein in the CNS using anti-receptor antisera.
  55. (1990). Characterization of dopamine release in the rat medial prefrontal cortex as assessed by in vivo microdialysis: comparison to the striatum.
  56. (1988). Characterization of in vivo dopamine release as determined by brain microdialysis after acute and subchronic implantations: methodological aspects.
  57. (1991). Characterization of the chemical architecture of carbon-fiber microelectrodes.
  58. (1986). Chronic use of intracerebral microdialysis for the in vivo measurements of 3, 4, dihydroxyphenylethylamine and its metabolite 3, 4, dihydroxyphenylacetic acid.
  59. (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
  60. (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.
  61. (2000). Cloning, expression, functional coupling and pharmacological characterization of the rat dopamine D4 receptor.
  62. (1997). Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits.
  63. (1999). Cognition, schizophrenia, and the atypical antipsychotic drugs.
  64. (2006). Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.
  65. (1999). Cognitive dysfunction in schizophrenia: unifying basic research and clinical aspects.
  66. (2005). Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans.
  67. (1999). Comparative pharmacological and functional analysis of the human dopamine D4.2 and D4.10 receptor variants.
  68. (2004). Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5). Biochem Pharmacol,
  69. (2008). Comparison of methods for measuring absolute brain concentrations of drugs, following systemic administration;
  70. (2001). Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release.
  71. (1964). Conversion of L-tyrosine to 3,4-dihydroxyphenylalanine by cell-free preparations of brain and sympathetically innervated tissues.
  72. (2003). Cortical activation associated with the experience of auditory hallucinations and perception of human speech in schizophrenia: a PET correlation study.
  73. (1995). Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground.
  74. (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine.
  75. (1991). D1 dopamine receptors in prefrontal cortex: involvement in working memory.
  76. (1995). D2-family receptor distribution in human postmortem tissue: an autoradiographic study.
  77. (1996). D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes.
  78. (1998). Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling.
  79. (1999). Delineating muscarinic receptor functions.
  80. (1989). Determination of brain interstitial concentrations by microdialysis.
  81. (1986). Development of push-pull systems for perfusion of anatomically distinct regions of the brain of the awake animal.
  82. (1989). Differences in dopamine release and metabolism in rat striatal subregions following acute clozapine using in vivo microdialysis.
  83. (1988). Different roles of D-1 and D-2 dopamine receptors involved in locomotor activity of supersensitive mice.
  84. (1998). Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain.
  85. (2000). Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter.
  86. (2002). Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.
  87. (2001). Diffusion and related transport properties in brain tissue. Rep Prog Phys.
  88. (1997). Disruption of latent inhibition in the rat by the 5-HT2 agonist DOI: effects of MDL 100,907, clozapine, risperidone and haloperidol.
  89. (1993). Dissimilar patterns of degeneration in brain following four different addictive stimulants.
  90. (2000). Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex.
  91. (2001). Dopamine as a prolactin (PRL) inhibitor.
  92. (2000). Dopamine control of striatal gene expression during development: relevance to knockout mice for the dopamine transporter.
  93. (1998). Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
  94. (2001). Dopamine D4 receptor-deficient mice display cortical hyperexcitability.
  95. (1999). Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli.
  96. (2002). Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex.
  97. (1995). Dopamine D4-like receptor elevation in schizophrenia: cloned D2 and D4 receptors cannot be discriminated by raclopride competition against [3H]nemonapride.
  98. (1991). Dopamine in schizophrenia: a review and reconceptualization.
  99. (2000). Dopamine increases excitability of pyramidal neurons in primate prefrontal cortex.
  100. Dopamine neuronal transport kinetics and effects of amphetamine.
  101. (1994). Dopamine receptor pharmacology.
  102. (2004). Dopamine receptor signaling.
  103. (1999). Dopamine receptors and schizophrenia: contribution of molecular genetics and clinical neuropsychology.
  104. (1999). Dopamine receptors--physiological understanding to therapeutic intervention potential.
  105. (1998). Dopamine receptors: from structure to function.
  106. (1992). Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: a comparison of acute clozapine and haloperidol.
  107. (2007). Dopamine-mediated regulation of corticostriatal synaptic plasticity.
  108. (1992). Dopaminergic mechanisms in the pathogenesis of schizophrenia.
  109. (1995). Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia.
  110. (1973). Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity.
  111. (1997). Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method.
  112. (2001). Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex.
  113. (1967). Effect of phencyclidine in chronic schizophrenics.
  114. (1975). Effects of catecholamine releasing agents on synaptosomal dopamine biosynthesis: multiple pools of dopamine or multiple forms of tyrosine hydroxylase.
  115. (1989). Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.
  116. (2002). Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat.
  117. (2005). Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
  118. (1992). Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia".
  119. (2004). Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation.
  120. (2009). Evaluation of Metaquant microdialysis for measurement of absolute concentrations of amphetamine and dopamine in brain: a viable method for assessing pharmacokinetic profiles of drugs in the brain;
  121. (1984). Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.
  122. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev,
  123. (1999). Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition.
  124. (1992). Extracellular concentration and in vivo recovery of dopamine in the nucleus accumbens using microdialysis.
  125. (1998). Extracellular space structure revealed by diffusion analysis.
  126. (1997). Factors that influence microdialysis recovery. Comparison of experimental and theoretical microdialysis recoveries in rat liver.
  127. (1997). Full-length review Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood–brain barrier,
  128. (1997). Functional and anatomical aspects of prefrontal pathology in schizophrenia.
  129. (1974). Functional correlates of dopamine neurotransmission.
  130. (1999). Functional hyperdopaminergia in dopamine transporter knock-out mice.
  131. (2002). G proteincoupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase.
  132. (2000). GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia.
  133. (2005). Getting to the source of schizophrenia.
  134. (2003). Glutamatergic animal models of schizophrenia.
  135. (1994). Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release.
  136. (1980). Heterogeneity of cerebral capillary flow in man and its consequences for estimation of blood-brain barrier permeability.
  137. (2000). Heterogeneity of the mesotelencephalic dopamine fibers: physiology and pharmacology.
  138. (1998). Human D2 and D4 dopamine receptors couple through betagamma G-protein subunits to inwardly rectifying K+ channels (GIRK1) in a Xenopus oocyte expression system: selective antagonism by L-741,626 and L-745,870 respectively.
  139. (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.
  140. (2001). Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit.
  141. (1997). I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor.
  142. (2001). Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia.
  143. (2008). Impairment of working memory maintenance and response in schizophrenia: functional magnetic resonance imaging evidence.
  144. (1998). Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo.
  145. (1993). In vivo assessment of basal and drug-induced dopamine release in cortical and subcortical regions of the anesthetized primate.
  146. (1991). In vivo microdialysis sampling for pharmacokinetic investigations.
  147. (1987). In vivo microdialysis--a new approach to the analysis of neurotransmitters in the brain.
  148. (2005). In vivo neurochemical monitoring and the study of behaviour.
  149. (1986). In vivo voltammetry: some methodological considerations.
  150. (2001). Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis.
  151. (1992). Increased dopamine release in vivo in nucleus accumbens and caudate nucleus of the rat during drinking: a microdialysis study.
  152. (1998). Increased extracellular dopamine in the nucleus accumbens of the rat during associative learning of neutral stimuli.
  153. (2007). Influence of gender on working and spatial memory in the novel object recognition task in the rat.
  154. (2002). Inhibitors alter the spectrum and redox properties of monoamine oxidase A. Biochim Biophys Acta,
  155. (2008). Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm.
  156. (1997). Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization.
  157. (1993). Intracerebral microdialysis in the study of physiology and behaviour.
  158. (2003). Intracerebral microdialysis: 30 years as a tool for the neuroscientist.
  159. (1989). Intracerebral microdialysis: I. Experimental studies of diffusion kinetics.
  160. (1989). Intracerebral microdialysis: II. Mathematical studies of diffusion kinetics.
  161. (2001). Involvement of enhanced sensitivity of N-methyl-D-aspartate receptors in vulnerability of developing cortical neurons to methylmercury neurotoxicity.
  162. (1999). Involvement of the prelimbicinfralimbic areas of the rodent prefrontal cortex in behavioral flexibility for place and response learning.
  163. (2002). Involvement of the rat medial prefrontal cortex in novelty detection.
  164. (1989). Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine.
  165. (1985). Kinetic model for disposition of 6-mercaptopurine in monkey plasma and cerebrospinal fluid.
  166. (1984). Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex.
  167. (1997). L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
  168. (1993). Latent inhibition of conditioned dopamine release in rat nucleus accumbens.
  169. (1996). Localization of dopamine D4 receptors in GABAergic neurons of the primate brain.
  170. (1978). Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration.
  171. (1998). Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats.
  172. (2001). Long-trace interval eyeblink conditioning is impaired in mutant mice lacking the NMDA receptor subunit epsilon 1.
  173. (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia.
  174. (1985). Mass transfer in brain dialysis devices--a new method for the estimation of extracellular amino acids concentration.
  175. (1984). Measurement of neurotransmitter release by intracranial dialysis:. In: Measurement of neurotransmitter release in vivo.
  176. (2000). Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.
  177. (1997). Measuring quality of life in schizophrenia.
  178. (2005). Mechanisms of neurotransmitter release by amphetamines: a review.
  179. (2009). Mechanisms underlying persistent activity in a model PFC microcircuit.
  180. (1998). Methodological aspects of the use of a calibrator in in vivo microdialysis-further development of the retrodialysis method.
  181. (2000). Methodological issues in microdialysis sampling for pharmacokinetic studies, Advanced Drug Delivery Reviews, Volume 45,
  182. (2009). Methodologies to assess brain drug delivery in lead optimization.
  183. (1997). Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine.
  184. (2006). Microdialysis as a tool in local pharmacodynamics.
  185. (1999). Microdialysis for pharmacokinetic analysis of drug transport to the brain, Advanced Drug Delivery Reviews, Volume 36, Issue 2-3,
  186. (2000). Microdialysis in mice for drug delivery research. Adv Drug Deliv Rev,
  187. (2000). Microdialysis in the study of drug transporters in the CNS. Adv Drug Deliv Rev,
  188. (2008). Microdialysis of GABA and glutamate: analysis, interpretation and comparison with microsensors.
  189. (1989). Microdialysis of intercellular adenosine concentration in subcutaneous tissue in humans.
  190. (2006). Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution.
  191. (1997). Microdialysis--a new technique for monitoring local tissue events in the clinic.
  192. (1991). Microdialysis--principles and applications for studies in animals and man.
  193. (2005). Microdialysis--theoretical background and recent implementation in applied life-sciences.
  194. (1990). Microdialysis--theory and application.
  195. (2000). Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport.
  196. (1995). Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants.
  197. (2003). Monoamine transporters and psychostimulant drugs.
  198. (1995). More clues on "latent" schizophrenia point to developmental origins.
  199. (1998). Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling.
  200. (1999). Moving beyond findings: concepts and model-building in schizophrenia.
  201. (1992). Multiple dopamine D4 receptor variants in the human population.
  202. (1999). Muscarinic supersensitivity and impaired receptor desensitization in G proteincoupled receptor kinase 5-deficient mice.
  203. (1998). N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: a potent and selective dopamine D4 ligand.
  204. (1991). N-methyl-D-aspartate releases excitatory amino acids in rat corpus striatum in vivo.
  205. (2000). Network interactions in schizophrenia - therapeutic implications.
  206. (1994). Neural networks and schizophrenia.
  207. (1994). Neuronal injury produced by NMDA antagonists can be detected using heat shock proteins and can be blocked with antipsychotics.
  208. (1993). Neuronal vacuolization and necrosis induced by the noncompetitive N-methylD-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex.
  209. (1999). Neuropharmacological assessment of potential dopamine D4 receptor-selective radioligands.
  210. (2000). Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
  211. (1991). Neuropsychological function in schizophrenia. Selective impairment in memory and learning.
  212. (1999). NGD 94-1 as an agonist at human recombinant dopamine D4.4 receptors expressed in HEK293 cells.
  213. (2002). NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys.
  214. (2004). Novel antipsychotics in schizophrenia.
  215. (2008). On the rate and extent of drug delivery to the brain.
  216. (2005). PD-168077, a selective dopamine D4 receptor agonist, induces penile erection when injected into the paraventricular nucleus of male rats.
  217. (2006). Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.
  218. (2000). Pharmacokineticpharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats--a microdialysis study.
  219. (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review.
  220. (1997). Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966.
  221. (2007). Plasma and CNS concentrations of Gaboxadol in rats following subcutaneous administration.
  222. (1996). Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis.
  223. (1994). Protective action of dopamine against glutamate neurotoxicity in the retina.
  224. (1980). Psychopathology and communication problems in a family practice.
  225. (1982). Purine levels in the intact rat brain. Studies with an implanted perfused hollow fibre.
  226. (1994). Quantitative approaches to in vivo brain microdialysis.
  227. (1993). Quantitative microdialysis of neurotransmitters.
  228. (1993). Quantitative microdialysis under transient conditions.
  229. (2009). Quantitative microdialysis using modified ultraslow microdialysis: direct rapid and reliable determination of free brain concentrations with the MetaQuant technique.
  230. (1991). Quantitative microdialysis: analysis of transients and application to pharmacokinetics in brain.
  231. (1991). Quantitative microdialysis.
  232. (1998). Quinolinic acid in vivo synthesis rates, extracellular concentrations, and intercompartmental distributions in normal and immune-activated brain as determined by multiple-isotope microdialysis.
  233. (1991). Recent advances in the phencyclidine model of schizophrenia.
  234. (1995). Recent developments in the neuropharmacology of schizophrenia.
  235. (1999). Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells.
  236. (1998). Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats.
  237. (1996). Regional and cellular fractionation of working memory.
  238. (1987). Regional cerebral glucose phosphorylation and blood flow after insertion of a microdialysis fiber through the dorsal hippocampus in the rat.
  239. (2003). Regulation of NMDA receptors by dopamine D4 signaling in prefrontal cortex.
  240. (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.
  241. (1997). Reversal of phencyclidineinduced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide.
  242. (1991). Schizoaffective disorders.
  243. (1997). Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist.
  244. (1994). Schizophrenia and temporal lobe epilepsy. A neuropsychological analysis.
  245. (1997). Schizophrenia, psychosis, and the basal ganglia.
  246. (1997). Schizophrenia: a disorder of neurodevelopment?
  247. (1994). Schizophrenia: D4 receptor elevation. What does it mean?
  248. (1995). Schizophrenia: elevation of dopamine D4-like sites, using [3H]nemonapride and [125I]epidepride.
  249. (2004). Schizophrenia: from dopamine to glutamate and back.
  250. (2003). Schizophrenia: from phenomenology to neurobiology.
  251. (1990). Search after neurobiological profile of individual-specific features of Wistar rats.
  252. (1998). Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition.
  253. (2001). Self-monitoring enhances Wisconsin Card Sorting Test performance in patients with schizophrenia: performance is improved by simply asking patients to verbalize their sorting strategy.
  254. (1997). Sensitization to d-amphetamine after its repeated administration: evidence in EEG and behaviour.
  255. (1996). Signal transduction pathways modulated by the D2 subfamily of dopamine receptors.
  256. (2004). Simultaneous central nervous system distribution and pharmacokineticpharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats.
  257. (2002). Simultaneous determination of free-form amphetamine in rat's blood and brain by in-vivo microdialysis and liquid chromatography with fluorescence detection.
  258. (1992). Simultaneous measurement of extracellular morphine and serotonin in brain tissue and CSF by microdialysis in awake rats.
  259. (1990). Single photon emission computed tomography in phencyclidine and related drug abuse.
  260. (1990). Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro.
  261. (2000). Structure and function of dopamine receptors.
  262. (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
  263. (1959). Study of a new schizophrenomimetic drug; sernyl.
  264. (2007). Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbuminimmunoreactive expression in the rat.
  265. (1997). Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists.
  266. (1997). Substituted 4-aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D4 receptor.
  267. (1999). Symptom correlates of global measures of severity in schizophrenia.
  268. (1998). Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist.
  269. (2005). Systemic and prefrontal cortical NMDA receptor blockade differentially affect discrimination learning and set-shift ability in rats.
  270. (2004). Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.
  271. (1998). The agonist activities of the putative antipsychotic agents,
  272. (2000). The central role of the prefrontal cortex in directing attention to novel events.
  273. (2005). The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
  274. (1966). The concentrations of free amino acids and other electrolytes in cerebrospinal fluid, in vivo dialysate of brain, and blood plasma of the dog.
  275. (1984). The cortical cup technique,
  276. (1998). The cortical dopamine system: role in memory and cognition.
  277. (1998). The discovery of potent and selective dopamine D4 receptor antagonists.
  278. (2000). The dopamine D(4) receptor: one decade of research.
  279. (2003). The dopamine D4 receptors and mechanisms of antipsychotic atypicality.
  280. (2006). The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversallearning paradigm.
  281. (1999). The effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia.
  282. (2000). The emergence of modern neuroscience: some implications for neurology and psychiatry.
  283. (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
  284. (1996). The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory.
  285. (1986). The migration of substances in the neuronal microenvironment.
  286. (2004). The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected].
  287. (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.
  288. (2003). The novel dopamine D4 receptor agonist (PD 168,077 maleate): doses with different effects on locomotor activity are without effect in classical conditioning.
  289. (2003). The price of innovation: new estimates of drug development costs.
  290. (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex.
  291. (1998). The rat brain in stereotaxic coordinates.
  292. (1992). The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia.
  293. (1998). The role of negative symptoms and cognitive dysfunction in schizophrenia outcome.
  294. (1999). The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice.
  295. (1996). The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach.
  296. (1991). The use of an "internal standard" for control of the recovery in microdialysis.
  297. (2000). The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev,
  298. (1980). The utility of the Wisconsin Card Sorting Test in detecting and localizing frontal lobe lesions.
  299. (2001). Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications.
  300. (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
  301. (2000). Use of microdialysis in drug delivery studies. Adv Drug Deliv Rev,
  302. (1992). Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).
  303. (1990). Utilization of microdialysis for assessing the release of mesotelencephalic dopamine following clozapine and other antipsychotic drugs.
  304. (1998). What role models? Commentary on Robbins' homology in behavioural pharmacology: an approach to animal models of human cognition.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.